These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26980172)

  • 1. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
    Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
    Cathomas R; von Moos R
    Ann Oncol; 2009 Sep; 20(9):1606-1607. PubMed ID: 19622591
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
    Mutlu H; Büyükçelik A; Akça Z; Erden A
    J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eruptive nevi in a patient with metastatic breast cancer.
    Calleja-Algarra A; Aragón-Miguel R; Velasco-Tamariz V; Andrés-Lencina JJ; Prieto Barrios M; Maroñas Jiménez L; Ortiz Romero PL; Monsálvez Honrubia V
    Int J Dermatol; 2017 Dec; 56(12):1508-1509. PubMed ID: 28960262
    [No Abstract]   [Full Text] [Related]  

  • 8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
    Schaid DJ; Spraggs CF; McDonnell SK; Parham LR; Cox CJ; Ejlertsen B; Finkelstein DM; Rappold E; Curran J; Cardon LR; Goss PE
    J Clin Oncol; 2014 Aug; 32(22):2296-303. PubMed ID: 24687830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
    Sardesai SD; Storniolo AM
    Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine-induced Subacute Cutaneous Lupus Erythematosus.
    Rocha A; Almeida HL; Zerwes G; Oliveira Filho UL
    An Bras Dermatol; 2019; 94(5):618-619. PubMed ID: 31777367
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.
    Le Saux O; You B; Freyer G
    Clin Breast Cancer; 2014 Jun; 14(3):e89-94. PubMed ID: 24424314
    [No Abstract]   [Full Text] [Related]  

  • 13. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib in metastatic breast cancer.
    Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
    Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.
    Fontanella C; Lederer B; Nekljudova V; Untch M; von Minckwitz G; Loibl S
    J Clin Oncol; 2014 Oct; 32(30):3458-9. PubMed ID: 25225430
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
    Vrdoljak E; Boban M; Ban M
    J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Chao YL; Anders CK
    Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.